1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Colorectal cancer

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer

Technology appraisal guidance [TA61] Published: 27 May 2003

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 Clinical need and practice
  • 3 The technology
  • 4 Evidence and interpretation
  • 5 Further research
  • 6 Implications for the NHS
  • 7 Implementation and audit
  • 8 Related guidance
  • Appendix A. Appraisal Committee members
  • Appendix B. Sources of evidence considered by the Committee
  • Appendix C. The use of capecitabine and tegafur with uracil for metastatic colorectal cancer
  • Appendix D. Detail on criteria for audit of the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
  • Update information
Download guidance (PDF)

Guidance

  • Next

Appendix C. The use of capecitabine and tegafur with uracil for metastatic colorectal cancer

Appendix C. The use of capecitabine and tegafur with uracil for metastatic colorectal cancer

A summary of this guidance for people with colorectal cancer and the public can be found on our website.


  • Next